Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.


Friday, 17 May 2013 07:50am EDT 

Oramed Pharmaceuticals Inc announced that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application(IND) for ORMD-0801, its oral insulin capsule. 

Company Quote

4.46
 +0.00%
26 Dec 2014